Developer docs
API playgroundTry for free, no card

Search company profiles

Rapid Medical

Full company profile

uuid0000c8r

Namestring
Rapid Medical
Legal namestring
Rapid Medical Ltd.
Company typeenum
Private
Founded yearint
2016
Descriptiontext

Rapid Medical is an Israeli-founded neurovascular medical device company headquartered in Yokneam, Israel, that develops and commercializes proprietary adjustable interventional devices for the treatment of ischemic and hemorrhagic stroke. The company's core technology platform enables real-time, intra-procedural adjustment of devices in response to patient anatomy — a capability the company describes as unique in the category. Its three product lines are the TIGERTRIEVER family (adjustable stent retrievers for mechanical thrombectomy, including the standard TIGERTRIEVER plus TIGERTRIEVER 13, TIGERTRIEVER XL, and TIGERTRIEVER 25 sizes), the COMANECI temporary aneurysm embolization assist device with an expanded CE mark for vasospasm treatment, and the DRIVEWIRE steerable neurovascular guidewire. All products are protected by 100+ issued patents, supported by 75+ clinical publications, and have cumulatively been used to treat more than 40,000 patients across 30+ countries.

The company's business model is enterprise B2B hardware sales of single-use interventional devices to hospitals and stroke treatment centers, with direct field sales coverage in the US (Southlake, Texas), Germany (Frankfurt), and the UK (London), supplemented by exclusive distribution partnerships — notably Kaneka for Japan and MicroPort as strategic investor and channel partner. Revenue is generated per procedure through device sales; pricing is not publicly disclosed. Rapid Medical has secured FDA clearance for all core products, CE marking for the European portfolio, regulatory approval in China, and Japanese approval via Kaneka. The company has raised approximately $79 million across three disclosed rounds, with the $50 million Series D in 2021 led by MicroPort. Leadership is anchored by co-founder and CEO Ronen Eckhouse alongside an executive team with prior operating experience at Medtronic, BTG-acquired Galil Medical, and several Israeli MedTech ventures.

Short descriptiontext

Rapid Medical is an Israeli neurovascular medical device company that develops and commercializes proprietary, real-time adjustable devices — TIGERTRIEVER thrombectomy systems, COMANECI aneurysm embolization assist, and DRIVEWIRE steerable guidewires — selling them to hospitals and stroke centers in 30+ countries.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersYoqne`am `illit, Israel
HQ citystring
Yoqne`am `illit
HQ countrystring
Israel
HQ regionstring
Middle East
Markets served

Serves global market

Offices4 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
neurovascular devices, thrombectomy devices, stroke intervention, aneurysm embolization, steerable guidewires
Industry2 codes
PRIMARYHLAHAFAJ
Thrombectomy, Embolic Protection & Stroke Intervention Devices
Healthcare & Life Sciences/Medical Devices & Diagnostics/Cardiovascular Devices (Stents, Valves, Rhythm Management)
SECONDARYHLAHAFAK
Vascular Access & Closure Devices (Sheaths, Guidewires, Closure Systems)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Cardiovascular Devices (Stents, Valves, Rhythm Management)
NAICS code2 codes
  • Electromedical and Electrotherapeutic Apparatus Manufacturing334510
  • Surgical and Medical Instrument Manufacturing339112
SIC code1 code
  • Surgical & Medical Instruments & Apparatus3841
Product category
Neurovascular Medical Devices
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Neurovascular Medical Devices
TypeHardware Sales
Description

Rapid Medical generates revenue through the sale of proprietary neurovascular devices including TIGERTRIEVER thrombectomy devices, COMANECI embolization assist devices, and DRIVEWIRE steerable guidewires to hospitals and healthcare systems globally.

finsmes.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Technology or R&D, Personnel, Supply Chain, Marketing or Sales, Operations, Others
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 3 records shown
1TIGERTRIEVER™
Description

Adjustable thrombectomy devices for ischemic stroke treatment, including TIGERTRIEVER 13 and TIGERTRIEVER 25

rapid-medical.com
+2 more records
Core offering1 text field

Rapid Medical develops and manufactures proprietary, remotely adjustable neurovascular medical devices for treating ischemic and hemorrhagic stroke. Its portfolio includes adjustable stent retriever thrombectomy devices (TIGERTRIEVER family), an adjustable aneurysm embolization assist device (COMANECI), and steerable neurovascular guidewires (DRIVEWIRE).

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • 86.3% success rate without symptomatic intracranial hemorrhage in DISTALS trial for medium vessel stroke
+1 more record
Product overview1 text field

Rapid Medical develops a portfolio of proprietary, remotely adjustable interventional neurovascular devices for treating ischemic and hemorrhagic stroke. The core products include the TIGERTRIEVER family (TIGERTRIEVER, TIGERTRIEVER 13, TIGERTRIEVER 25, TIGERTRIEVER XL) - adjustable thrombectomy/stent retriever devices for mechanical clot removal in ischemic stroke; COMANECI - an embolization assist device for wide-necked aneurysm treatment and vasospasm; and DRIVEWIRE - the world's first steerable neurovascular guidewire for precise catheter navigation. All products utilize proprietary manufacturing techniques enabling real-time adjustment during procedures to adapt to patient anatomy.

Product and service6 records
1TIGERTRIEVER
CategoryThrombectomy Devices
Description

The world's first and only FDA-cleared adjustable stent retriever for mechanical thrombectomy in acute ischemic stroke patients, enabling real-time control of expansion during clot retrieval.

2TIGERTRIEVER 13
CategoryThrombectomy Devices
Description

Smallest adjustable thrombectomy device, designed for distal vessel occlusion treatment in neurovascular procedures.

3TIGERTRIEVER 25
CategoryThrombectomy Devices
Description

Adjustable thrombectomy device in the TIGERTRIEVER family for ischemic stroke treatment.

4TIGERTRIEVER XL
CategoryThrombectomy Devices
Description

Larger-format adjustable stent retriever variant of TIGERTRIEVER for thrombectomy procedures.

5COMANECI
CategoryAneurysm Embolization Devices
Description

First-of-its-kind adjustable, temporary coil occlusion/embolization assist device used during treatment of intracranial aneurysms, providing bridge support without flow arrest.

6DRIVEWIRE 24
CategoryNeurovascular Guidewires
Description

Steerable neurovascular guidewire designed for navigation through tortuous cerebral vasculature during endovascular procedures.

Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierMajorTypeChannel Partner/ Reseller/ DistributorAnnounced on2023-12-01
Description

Rapid Medical announced Japanese approval and exclusive partnership with Kaneka for TIGERTRIEVER - the world's only adjustable thrombectomy device. Kaneka has exclusive rights to distribute TIGERTRIEVER in Japan, representing a significant distribution partnership for the Asian market.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight8 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Penumbra is a direct competitor in mechanical thrombectomy with its Indigo aspiration and RED reperfusion catheter systems for ischemic stroke. It competes head-to-head with TIGERTRIEVER in stroke centers globally and is one of the fastest-growing neurovascular players.

TypeBroad incumbent
Description

Medtronic offers the Solitaire stent retriever and Riptide aspiration system for stroke thrombectomy within a large diversified neurovascular and broader MedTech portfolio. Rapid Medical's President Americas came from Medtronic's neurovascular division, underscoring direct overlap in customer base and product category.

TypeBroad incumbent
Description

Stryker's Neurovascular division sells the Trevo stent retriever for ischemic stroke and a broader portfolio of access and embolization devices. As one of the largest incumbent neurovascular players, Stryker represents a direct competitor in Rapid Medical's core thrombectomy and access categories.

4Johnson & Johnson (Cerenovus)
TypeBroad incumbent
Description

Cerenovus, J&J's neurovascular business, offers stent retrievers (EmboTrap), access devices, and embolization products. It competes directly with Rapid Medical across ischemic and hemorrhagic stroke interventions within the J&J MedTech portfolio.

5MicroPort NeuroTech
TypeBroad incumbent
Description

MicroPort NeuroTech is the neurovascular affiliate of MicroPort, which is Rapid Medical's strategic parent and Series D lead. It sells competing neurovascular devices including Numen coils (which Rapid Medical has already used jointly), making it both a related-party distributor and a partial competitor.

TypeDirect peer
Description

Phenox is a Germany-based neurovascular device company offering stent retrievers, flow diverters, and access products for stroke treatment. It is a closely comparable European peer focused on the same procedural indications and hospital customer base as Rapid Medical.

TypeDirect peer
Description

Acandis is a German neurovascular specialist selling stent retrievers (APERIO), flow diverters, and embolization coils. It is a direct peer in thrombectomy and aneurysm treatment, serving the same European stroke centers as Rapid Medical.

TypeDirect peer
Description

Balt is a French neurovascular company offering a broad portfolio of stroke and aneurysm treatment devices, including stent retrievers (CATCH+) and flow diverters. It competes with Rapid Medical across ischemic and hemorrhagic stroke indications globally.

9MIVI Neuroscience
TypeEmerging player
Description

MIVI Neuroscience is a US-based emerging player developing novel stroke intervention devices including the Q aspiration catheter and an investigational stent retriever. It is a smaller-scale peer targeting overlapping ischemic stroke accounts and competing for trial and adoption mindshare with Rapid Medical.

TypeEmerging player
Description

Imperative Care is a US-based neurovascular company developing the Zoom stroke reperfusion system including aspiration catheters and a novel stent retriever. It is a venture-backed emerging competitor with overlapping procedural indications and a fast-growing sales effort in the same US accounts Rapid Medical targets.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers5 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles9 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds4 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors12 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Rapid Medical

Neurovascular Medical Devicesrapid-medical.com

Rapid Medical is an Israeli neurovascular medical device company that develops and commercializes proprietary, real-time adjustable devices — TIGERTRIEVER thrombectomy systems, COMANECI aneurysm embolization assist, and DRIVEWIRE steerable guidewires — selling them to hospitals and stroke centers in 30+ countries.

What Rapid Medical does

Rapid Medical is an Israeli-founded neurovascular medical device company headquartered in Yokneam, Israel, that develops and commercializes proprietary adjustable interventional devices for the treatment of ischemic and hemorrhagic stroke. The company's core technology platform enables real-time, intra-procedural adjustment of devices in response to patient anatomy — a capability the company describes as unique in the category. Its three product lines are the TIGERTRIEVER family (adjustable stent retrievers for mechanical thrombectomy, including the standard TIGERTRIEVER plus TIGERTRIEVER 13, TIGERTRIEVER XL, and TIGERTRIEVER 25 sizes), the COMANECI temporary aneurysm embolization assist device with an expanded CE mark for vasospasm treatment, and the DRIVEWIRE steerable neurovascular guidewire. All products are protected by 100+ issued patents, supported by 75+ clinical publications, and have cumulatively been used to treat more than 40,000 patients across 30+ countries.

The company's business model is enterprise B2B hardware sales of single-use interventional devices to hospitals and stroke treatment centers, with direct field sales coverage in the US (Southlake, Texas), Germany (Frankfurt), and the UK (London), supplemented by exclusive distribution partnerships — notably Kaneka for Japan and MicroPort as strategic investor and channel partner. Revenue is generated per procedure through device sales; pricing is not publicly disclosed. Rapid Medical has secured FDA clearance for all core products, CE marking for the European portfolio, regulatory approval in China, and Japanese approval via Kaneka. The company has raised approximately $79 million across three disclosed rounds, with the $50 million Series D in 2021 led by MicroPort. Leadership is anchored by co-founder and CEO Ronen Eckhouse alongside an executive team with prior operating experience at Medtronic, BTG-acquired Galil Medical, and several Israeli MedTech ventures.

Rapid Medical firmographics

Firmographics
Name
Rapid Medical
Legal name
Rapid Medical Ltd.
Website
https://rapid-medical.com
Company type
Private
Founded year
2016
Operating status
Operating
Headcount range
101–250 employees
Short description
Rapid Medical is an Israeli neurovascular medical device company that develops and commercializes proprietary, real-time adjustable devices — TIGERTRIEVER thrombectomy systems, COMANECI aneurysm embolization assist, and DRIVEWIRE steerable guidewires — selling them to hospitals and stroke centers in 30+ countries.
Ownership category
akta.pro rank

Rapid Medical industry classification

Industry
Product category
Neurovascular Medical Devices
NAICS
Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Surgical and Medical Instrument Manufacturing (339112)
SIC
Surgical & Medical Instruments & Apparatus (3841)
akta.pro industry
PRIMARYHLAHAFAJ
Thrombectomy, Embolic Protection & Stroke Intervention Devices
Healthcare & Life Sciences/Medical Devices & Diagnostics/Cardiovascular Devices (Stents, Valves, Rhythm Management)
SECONDARYHLAHAFAK
Vascular Access & Closure Devices (Sheaths, Guidewires, Closure Systems)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Cardiovascular Devices (Stents, Valves, Rhythm Management)

Keywords

  • Neurovascular devices
  • Thrombectomy devices
  • Stroke intervention
  • Aneurysm embolization
  • Steerable guidewires

Where Rapid Medical is headquartered

Location

Headquarters

HQ city
Yoqne`am `illit
HQ country
Israel
HQ region
Middle East

Offices4 records

Markets served

Rapid Medical business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Supply Chain, Marketing or Sales, Operations, Others

Revenue model

  1. Neurovascular Medical Devices: Rapid Medical generates revenue through the sale of proprietary neurovascular devices including TIGERTRIEVER thrombectomy devices, COMANECI embolization assist devices, and DRIVEWIRE steerable guidewires to hospitals and healthcare systems globally.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Rapid Medical product offering

Product offering

Core offering

Rapid Medical develops and manufactures proprietary, remotely adjustable neurovascular medical devices for treating ischemic and hemorrhagic stroke. Its portfolio includes adjustable stent retriever thrombectomy devices (TIGERTRIEVER family), an adjustable aneurysm embolization assist device (COMANECI), and steerable neurovascular guidewires (DRIVEWIRE).

Product overview

Rapid Medical develops a portfolio of proprietary, remotely adjustable interventional neurovascular devices for treating ischemic and hemorrhagic stroke. The core products include the TIGERTRIEVER family (TIGERTRIEVER, TIGERTRIEVER 13, TIGERTRIEVER 25, TIGERTRIEVER XL) - adjustable thrombectomy/stent retriever devices for mechanical clot removal in ischemic stroke; COMANECI - an embolization assist device for wide-necked aneurysm treatment and vasospasm; and DRIVEWIRE - the world's first steerable neurovascular guidewire for precise catheter navigation. All products utilize proprietary manufacturing techniques enabling real-time adjustment during procedures to adapt to patient anatomy.

Differentiator

Problem solved

Functional benefit

Brands

  • TIGERTRIEVER™: Adjustable thrombectomy devices for ischemic stroke treatment, including TIGERTRIEVER 13 and TIGERTRIEVER 25
  • COMANECI™
  • DRIVEWIRE™

Products and services

  • TIGERTRIEVER The world's first and only FDA-cleared adjustable stent retriever for mechanical thrombectomy in acute ischemic stroke patients, enabling real-time control of expansion during clot retrieval.
  • TIGERTRIEVER 13 Smallest adjustable thrombectomy device, designed for distal vessel occlusion treatment in neurovascular procedures.
  • TIGERTRIEVER 25 Adjustable thrombectomy device in the TIGERTRIEVER family for ischemic stroke treatment.
  • TIGERTRIEVER XL Larger-format adjustable stent retriever variant of TIGERTRIEVER for thrombectomy procedures.
  • COMANECI First-of-its-kind adjustable, temporary coil occlusion/embolization assist device used during treatment of intracranial aneurysms, providing bridge support without flow arrest.
  • DRIVEWIRE 24 Steerable neurovascular guidewire designed for navigation through tortuous cerebral vasculature during endovascular procedures.

Quantifiable outcome

  • 86.3% success rate without symptomatic intracranial hemorrhage in DISTALS trial for medium vessel stroke
  • +1 more outcomes

Companies that use Rapid Medical

Customer profile

Named customers5 records

Segments1 record

Ideal customer profiles1 record

Rapid Medical technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Rapid Medical partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • KanekamajorChannel Partner/ Reseller/ Distributor · 1 December 2023Rapid Medical announced Japanese approval and exclusive partnership with Kaneka for TIGERTRIEVER - the world's only adjustable thrombectomy device. Kaneka has exclusive rights to distribute TIGERTRIEVER in Japan, representing a significant distribution partnership for the Asian market.

Scale indicators6 records

Recent moves6 records

Expansion highlights8 records

Rapid Medical competitors and assessment

Company assessment

Direct peers

  • Penumbra: Penumbra is a direct competitor in mechanical thrombectomy with its Indigo aspiration and RED reperfusion catheter systems for ischemic stroke. It competes head-to-head with TIGERTRIEVER in stroke centers globally and is one of the fastest-growing neurovascular players.
  • Phenox: Phenox is a Germany-based neurovascular device company offering stent retrievers, flow diverters, and access products for stroke treatment. It is a closely comparable European peer focused on the same procedural indications and hospital customer base as Rapid Medical.
  • Acandis: Acandis is a German neurovascular specialist selling stent retrievers (APERIO), flow diverters, and embolization coils. It is a direct peer in thrombectomy and aneurysm treatment, serving the same European stroke centers as Rapid Medical.
  • Balt: Balt is a French neurovascular company offering a broad portfolio of stroke and aneurysm treatment devices, including stent retrievers (CATCH+) and flow diverters. It competes with Rapid Medical across ischemic and hemorrhagic stroke indications globally.

Broad incumbents

  • Medtronic: Medtronic offers the Solitaire stent retriever and Riptide aspiration system for stroke thrombectomy within a large diversified neurovascular and broader MedTech portfolio. Rapid Medical's President Americas came from Medtronic's neurovascular division, underscoring direct overlap in customer base and product category.
  • Stryker: Stryker's Neurovascular division sells the Trevo stent retriever for ischemic stroke and a broader portfolio of access and embolization devices. As one of the largest incumbent neurovascular players, Stryker represents a direct competitor in Rapid Medical's core thrombectomy and access categories.
  • Johnson & Johnson (Cerenovus): Cerenovus, J&J's neurovascular business, offers stent retrievers (EmboTrap), access devices, and embolization products. It competes directly with Rapid Medical across ischemic and hemorrhagic stroke interventions within the J&J MedTech portfolio.
  • MicroPort NeuroTech: MicroPort NeuroTech is the neurovascular affiliate of MicroPort, which is Rapid Medical's strategic parent and Series D lead. It sells competing neurovascular devices including Numen coils (which Rapid Medical has already used jointly), making it both a related-party distributor and a partial competitor.

Emerging players

  • MIVI Neuroscience: MIVI Neuroscience is a US-based emerging player developing novel stroke intervention devices including the Q aspiration catheter and an investigational stent retriever. It is a smaller-scale peer targeting overlapping ischemic stroke accounts and competing for trial and adoption mindshare with Rapid Medical.
  • Imperative Care: Imperative Care is a US-based neurovascular company developing the Zoom stroke reperfusion system including aspiration catheters and a novel stent retriever. It is a venture-backed emerging competitor with overlapping procedural indications and a fast-growing sales effort in the same US accounts Rapid Medical targets.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Rapid Medical social profiles

Digital presence

Rapid Medical compliance and trust

Trust signal

Compliance2 records

Rapid Medical financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Rapid Medical leadership team

Management profile

Number of profiles

Profiles9 records

Rapid Medical funding detail

Funding detail

Funding overview

Funding rounds4 records

Investors12 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Rapid Medical M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Rapid Medical

What does Rapid Medical do?

Rapid Medical develops and manufactures proprietary, remotely adjustable neurovascular medical devices for treating ischemic and hemorrhagic stroke. Its portfolio includes adjustable stent retriever thrombectomy devices (TIGERTRIEVER family), an adjustable aneurysm embolization assist device (COMANECI), and steerable neurovascular guidewires (DRIVEWIRE).

Is Rapid Medical a public or private company?

Rapid Medical is a private company. It is classified as venture growth investor backed and is currently operating.

When was Rapid Medical founded?

Rapid Medical was founded in 2016. It employs 101 to 250 people.

Where is Rapid Medical based?

Rapid Medical is headquartered in Yoqne`am `illit, Israel, in the Middle East region.

How does Rapid Medical make money?

One revenue line is on record: neurovascular Medical Devices.

Who are Rapid Medical's main competitors?

Direct peers on record are Penumbra, Phenox, Acandis and Balt. Broad incumbents are Medtronic, Stryker, Johnson & Johnson (Cerenovus) and MicroPort NeuroTech. Emerging players are MIVI Neuroscience and Imperative Care.

Does Rapid Medical have an API?

No public API is recorded for Rapid Medical.

What industry is Rapid Medical in?

Rapid Medical's product category is Neurovascular Medical Devices. Its primary akta.pro industry code is HLAHAFAJ, Thrombectomy, Embolic Protection & Stroke Intervention Devices, with a secondary code of HLAHAFAK, Vascular Access & Closure Devices (Sheaths, Guidewires, Closure Systems). Its NAICS code is 334510 and its SIC code is 3841.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Mpo-magFDA Clears Rapid Medical’s DRIVEWIRE 35The FDA cleared Rapid Medical's DRIVEWIRE 35, a steerable 0.035-inch guidewire for stroke and intravascular procedures. Jeremy Rempel performed the first clinical cases, navigating catheters to treat intracranial occlusions. The wire adds active steering to compatible catheters, aiming to simplify access and save time.BioSpaceRapid Medical Announces FDA Clearance of DRIVEWIRE™ 35 and First Stroke CasesRapid Medical received FDA clearance for DRIVEWIRE 35, the first steerable 0.035-inch guidewire, announced at SNIS. Jeremy Rempel performed the first clinical cases, navigating catheters to treat an intracranial occlusion. The wire adds active steering to compatible catheters, building on nearly 5,000 DRIVEWIRE 24 cases.Financial PostRapid Medical Announces FDA Clearance of DRIVEWIRE™ 35 and First Stroke CasesRapid Medical announced FDA clearance of DRIVEWIRE 35, the first steerable 0.035-inch guidewire designed to help physicians reach treatment sites during stroke and intravascular procedures, announced at the SNIS 23rd Annual Meeting. Dr. Jeremy Rempel of the University of Alberta Hospital in Edmonton, Canada performed the first clinical cases worldwide, successfully navigating catheters to treat an intracranial occlusion. The device adds controlled tip deflection and active steering to compatible catheters, allowing physicians to articulate the catheter tip through complex anatomy and potentially reduce procedure time.FinancialContent Business PageRapid Medical Announces FDA Clearance of DRIVEWIRE™ 35 and First Stroke CasesRapid Medical announced FDA clearance of DRIVEWIRE™ 35, the first steerable 0.035-inch guidewire designed for stroke and other intravascular procedures. The device enables physicians to actively steer and shape the wire inside vessels, allowing catheters to navigate complex anatomy and reach treatment sites more efficiently. Dr. Jeremy Rempel at the University of Alberta Hospital in Edmonton, Canada, performed the first clinical cases worldwide.MorningstarRapid Medical Announces FDA Clearance of DRIVEWIRE™ 35 and First Stroke CasesRapid Medical received FDA clearance for DRIVEWIRE 35, a steerable 0.035-inch guidewire, announced at the SNIS meeting. Dr. Jeremy Rempel performed the first clinical cases, navigating a catheter to treat an intracranial occlusion. The device builds on nearly 5,000 DRIVEWIRE 24 cases.Business Wire BlogRapid Medical™ Completes Initial Neurovascular Cases in the USA Following FDA Clearance of Its Active Access SolutionRapid Medical has completed its initial neurovascular procedures in the USA using its DRIVEWIRE 24 device following FDA clearance. The cases, performed by Dr. Shahram Majidi at Mount Sinai Health System, demonstrated the device's ability to navigate complex vascular anatomy for treating arterial occlusions and aneurysms. This marks the first clinical use of the platform in the US, highlighting its potential to improve procedural efficiency and safety.Business Wire BlogRapid Medical Announces FDA Clearance of DRIVEWIRE™ 35 and First Stroke CasesRapid Medical announced FDA clearance of DRIVEWIRE 35, the first steerable 0.035-inch guidewire designed for stroke and other intravascular procedures, with the announcement made at the Society of NeuroInterventional Surgery's 23rd Annual Meeting. The device uses controlled tip deflection to allow physicians to shape the wire inside the vessel and actively steer compatible catheters through complex anatomy, building on nearly 5,000 prior DRIVEWIRE 24 cases. Dr. Jeremy Rempel of University of Alberta Hospital in Edmonton, Canada, performed the first clinical cases worldwide, successfully navigating catheters to treat an intracranial occlusion without crossing the clot.Business Wire BlogRapid Medical™’s TIGERTRIEVER™ 13 Demonstrates Promising 90-Day Outcomes in DISTALS Trial, Reinforcing Pivotal Safety and Efficacy FindingsRapid Medical presented full DISTALS trial results at ESOC 2026, showing TIGERTRIEVER 13 safely restores blood flow in distal and medium vessel occlusion stroke. At 90 days, 41.2% of patients had little or no disability versus 38.2% with medical therapy, and 69% of moderate-to-severe patients improved by at least one level. The company plans to pursue FDA clearance based on these results.Business Wire BlogRapid Medical™ Announces FDA Clearance of TIGERTRIEVER™ 25 and First Clinical CasesRapid Medical announced U.S. FDA clearance of TIGERTRIEVER 25, the largest thrombectomy device, and its first clinical cases in large vessel occlusion stroke. The device features a 53 mm capture length and real-time force control, enabling first-pass success in challenging anatomy.BioSpaceRapid Medical™ Completes Enrollment in DISTALS Trial Evaluating TIGERTRIEVER 13™ for Distal Vessel OcclusionsRapid Medical announced the completion of patient enrollment in the DISTALS Trial, a multicenter randomized study evaluating the TIGERTRIEVER 13 device for treating distal medium vessel occlusions in acute ischemic stroke patients. The trial, which is investigating a condition that represents up to 40% of all ischemic strokes, reported an interim safety analysis confirming no safety concerns with the device. The completion of enrollment marks a significant milestone toward generating clinical data to guide the next evolution of stroke treatment.